In case of equivalent degree of the decrease in LDL-C levels , 24-week combination therapy with atorvastatin and ezetimibe , unlike rosuvastatin treatment , induced increases in basal glycemia , insulinemia , HbA1c , and HOMA-IR index irrespective of the presence of carbohydrate metabolism disturbances before treatment .